New presentations of Viread launched and licence extended for use in younger patients

The nucleotide analogue tenofovir (Viread) has been licensed for use in young children with HIV infection and adolescents with hepatitis B.

Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY
Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY

Viread can now be prescribed, in combination with other antiretrovirals, for children aged 2 years and older with HIV-1 infection. In addition, it may be used to treat chronic hepatitis B in adolescents aged 12 years and older with compensated liver disease, evidence of active viral replication, persistently elevated ALT levels and histological evidence of active inflammation and/or fibrosis.

New tablets and granules now available

In order to support dosing in children aged 6–12 years, Gilead has launched three new strengths of Viread tablets: 123mg (for children 17–22kg); 163mg (for children 22–28kg); and 204mg (for children 28–55kg). An oral granule formulation is also now available for children aged 2–6 years and for patients of all ages when a solid dosage form is not appropriate. The granules should be mixed with soft food (eg, yoghurt) before being taken.

Discontinue if renal dysfunction develops in children

Tenofovir is not recommended for use in children with renal impairment and should be discontinued in children who develop renal impairment.

View Viread drug records

Further information: Gilead Sciences

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.